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Abstract
Background: There is a paucity of data regarding molecular markers that identify the phenotype
of the tendon cell. This study aims to quantify gene expression markers that distinguish between
tendon fibroblasts and other mesenchymal cells which may be used to investigate tenogenesis.
Methods: Expression levels for 12 genes representative of musculoskeletal tissues, including the
proposed tendon progenitor marker scleraxis, relative to validated reference genes, were
evaluated in matched samples of equine tendon (harvested from the superficial digital flexor
tendon), cartilage and bone using quantitative PCR (qPCR). Expression levels of genes associated
with tendon phenotype were then evaluated in healthy, including developmental, and diseased
equine tendon tissue and in tendon fibroblasts maintained in both monolayer culture and in three
dimensional (3D) collagen gels.
Results: Significantly increased expression of scleraxis was found in tendon compared with bone
(P = 0.002) but not compared to cartilage. High levels of COL1A2 and scleraxis and low levels of
tenascin-C were found to be most representative of adult tensional tendon phenotype. While,
relative expression of scleraxis in developing mid-gestational tendon or in acute or chronically
diseased tendon did not differ significantly from normal adult tendon, tenascin-C message was
significantly upregulated in acutely injured equine tendon (P = 0.001). Relative scleraxis gene
expression levels in tendon cell monolayer and 3D cultures were significantly lower than in normal
adult tendon (P = 0.002, P = 0.02 respectively).
Conclusion:  The findings of this study indicate that high expression of both COL1A2 and
scleraxis, and low expression of tenascin-C is representative of a tensional tendon phenotype. The
in vitro culture methods used in these experiments however, may not recapitulate the phenotype
of normal tensional tendon fibroblasts in tissues as evidenced by gene expression.
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Background
Tendon injuries are a significant cause of morbidity in
both man and veterinary species and are reported to rep-
resent 30% of the musculoskeletal caseload in a one year
study of human general practitioners [1]. Injury to the
equine superficial digital flexor tendon (SDFT) poses a
significant problem amongst racing Thoroughbreds with
a reported incidence of 11–43% [2,3]. The extracellular
matrix (ECM) of flexor tendons has evolved not only to
both transmit forces from muscle to bone but also as an
elastic energy store for efficient locomotion [4]. However,
once a tendon has been injured a fibrous repair response
ensues which, whilst being very efficient at repairing the
damaged tissue, does not regenerate the original tendon
matrix [5]. The fibrous scar tissue does not recapitulate the
unique parallel collagen fibre alignment found in normal
tendon. Consequently, the healed tendon does not retain
the biomechanical properties of the original tendon prior
to injury [5] and re-injury rates in horses can be as high as
56% [6].
The poor clinical outcome associated with tendon injury
and the limited capacity for regeneration of injured ten-
don have resulted in a growing interest in the use of tissue
engineering approaches for tendon therapy in both man
and animals [7]. Objective demonstration of successful
regeneration requires the identification of markers of
tenogenesis. However, currently there are no specific
molecular markers that can be used to characterise tendon
fibroblasts [8] and identify relevant differentiation and
repair. Verification of the success of tendon tissue engi-
neering interventions is currently based on histological
analysis and mechanical testing [9]. Identification of per-
tinent gene expression would be beneficial in confirming
cell differentiation to a relevant tendon cell phenotype.
Expression of key matrix genes within tissue engineered
constructs has also been used to identify such differentia-
tion, although validation of the relevance of the candidate
marker genes has not yet been performed [10]. Unfortu-
nately many of these key matrix genes are expressed in a
variety of mesenchymal tissues and therefore may not be
sufficiently discriminatory. In contrast, the genes
COL2A1, COL10A1 and SOX9 are well accepted as being
representative of chondrogenic differentiation [11] and
Runx2 and osteopontin are discriminating for osteogenic
differentiation [11]. In the current study eleven genes were
selected as representative of tendon, cartilage and bone
and quantified in these musculoskeletal tissues to identify
which of these genes were most discriminating for a ten-
don phenotype.
Collagen type I forms 95% of the collagen content of nor-
mal adult tendons, the remaining 5% constitutes small
amounts of collagen types III, V, VI, XII and XIV [12]. Fol-
lowing acute rupture of the human Achilles tendon or
equine SDFT gene expression of collagen types I, III and V
is increased [13-16]. Tenascin-C is also up regulated fol-
lowing tissue wounding [17] and in degenerate tendinop-
athy [18]. Other important tendon matrix components
include the small leucine rich proteoglycans (lumican,
decorin, biglycan and fibromodulin). The role of these
smaller matrix components has been demonstrated to be
important in collagen fibrillogenesis [19]. In addition the
glycoproteins such as cartilage oligomeric matrix protein
(COMP) and tenascin-C are understood to be involved in
collagen fibrillogenesis [20-22].
COMP is an extracellular matrix glycoprotein that is abun-
dant in tissues subjected to load. Levels of COMP increase
until skeletal maturity is reached after which time levels
gradually decline [20]. Tenomodulin is a type II trans-
membrane glycoprotein that is preferentially expressed in
dense connective tissues. Mice lacking tenomodulin have
tendons with a disrupted fibril structure and exhibit
severely reduce tendon fibroblast proliferation [23]. Ten-
omodulin has been reported to be a good phenotype
marker for tendon fibroblasts [24]. Decorin is a member
of the SLRPs that have been shown to be important in
control of collagen fibrillogenesis [25]. Recent investiga-
tions have highlighted scleraxis as a specific marker of ten-
don progenitor cells [26-28]. Furthermore, scleraxis null
mutant mice have distinct tendon defects [26]. Runx2 is
an osteogenic transcription factor [11]. Osteopontin is a
glycoprotein found in bone and forms part of the inor-
ganic component of bone. Osteomodulin is a keratan sul-
phate proteoglycan found in the ECM of bone and
thought to be a marker of osteoblast maturation [29].
SOX9 is a transcription factor important in chondrocyte
regulation and is frequently used to identify chondrogenic
differentiation [11].
The study performed here was designed to identify the
presence of the eleven genes in normal tendon and quan-
tify their expression levels in tendon compared to other
musculoskeletal tissues. The expression of key genes
which could identify an adult tendon phenotype were
then characterised both in clinical cases of tendinopathy
of the equine SDFT, as well as during development. Fur-
thermore the expression profile of these genes was charac-
terised in-vitro in both monolayer and three dimensional
(3D) cultures of tendon fibroblasts to identify whether
such models fully recapitulate the tendon phenotype.
Methods
Tissue samples
Tissue samples were obtained from animals subjected to
euthanasia for clinical reasons other than orthopaedic dis-
ease. Full informed written consent was obtained from
animal owners for all tissue collection and tissue collec-
tion was subject to ethical review. Three samples (10 × 5 ×BMC Musculoskeletal Disorders 2009, 10:27 http://www.biomedcentral.com/1471-2474/10/27
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2 mm) of equine superficial digital flexor tendon were
obtained from the mid-metacarpal region from skeletally
mature (aged 4–10 years) horses free of clinical orthopae-
dic disease. Matched cartilage samples (10 × 3 × 0.5 mm)
were harvested from the articular surface of the distal
aspect of the third metacarpal bone of the same donors
with bone (10 × 5 × 2 mm) being harvested from the dis-
tal metacarpal epiphysis. Further samples were collected
from five skeletally immature animals (three mid-gesta-
tional foetuses and two yearlings). All tissue specimens
were grossly normal on post mortem examination. Patho-
logical tissue specimens were collected from the mid-met-
acarpal region of the SDFT of 3 horses with acute (< 6
weeks duration) and 3 horses with chronic (> 6 months
duration) tendinopathy. All samples were obtained
within 4 hours of euthanasia and collected into
RNAlater™ (Ambion, Applied Biosystems). Samples were
stored at 4°C for 24 hours and then frozen at -80°C until
used for RNA extraction.
Monolayer cell culture
For the cell culture experiments tendon samples were col-
lected from 4 adult (age 4–10 yrs), mixed breed horses
subjected to euthanasia. All tendons were free of pathol-
ogy on clinical and post mortem examination. Tendons
were collected from the SDFT at the level of the mid-met-
acarpus (tensional), within 4 hours of euthanasia. Sam-
ples were cut into 2 × 2 × 2 mm3 pieces and subjected to
collagenase type II (0.1%) digestion overnight in DMEM
(Sigma) containing 5% FCS, penicillin/streptomycin and
amphotericin) on an orbital shaker at 37°C. The isolated
tendon fibroblasts were cultured in 75 cm2  flasks in
DMEM containing 10% FCS, penicillin/streptomycin and
fungizone at 5% CO2 and 37°C until approximately 90%
confluent before passaging (usually 4–6 days for each pas-
sage). Cells were released from flasks with trypsin
(0.05%) and re-seeded into flasks at 5000 cells/cm2. Cul-
ture medium was changed every 3–4 days. One millilitre
of Tri-Reagent (Sigma) was added to the remaining cells
for subsequent RNA extraction, these samples were stored
at -80°C. The cells were passaged 5 times for the 3 differ-
ent horses.
Three dimensional cell culture in collagen gels
Tendon fibroblasts harvested from the tensional area of
the SDFT as described above were cultured until conflu-
ent. Collagen gels were prepared following a method
described previously [30]. Briefly, following trypsinisa-
tion at the end of passage one, cells were counted and sus-
pended in 90% type I collagen gel (2 mg/ml) (Invitrogen),
10% 10 × DMEM (Sigma) using 1 × 106 cells/mL. Two
hundred microlitres of the collagen cell suspension were
cast in a trough mold (Trough loader, Flexcell Interna-
tional) centrally located in a Tissue train culture plate
(Flexcell International). The collagen gels were cultured at
5% CO2 in a humidified incubator at 37°C for 24 hours
prior to the addition of DMEM containing 10% FCS, pen-
icillin/streptomycin and amphotericin. Cell seeded colla-
gen gels were then cultured without dynamic load for 5
days.
RNA extraction and quantification
RNA was extracted using phenol/guanidine HCl reagents
(TriReagent™, Sigma) and isolated using the published
methods [31,32]. Tissue samples were pulverised for 1
minute at 2000 oscillations/minute in a liquid nitrogen
cooled dismembranator (Braun Mikro-Dismembrator
Vessel, Braun Biotech International, Melsungen, Ger-
many). A 1 mL aliquot of phenol/guanidine HCl reagents
(TriReagent™, Sigma) was added to the powdered tendon,
cartilage or bone. Two hundred microlitres of chloroform
was added to the microcentrifuge tubes prior to centrifu-
gation at 12,000 g for 10 minutes. RNA was extracted from
the aqueous phase using a commercially available RNA
purification kit (RNeasy Mini Kit, Qiagen). Digestion of
DNA was carried out using a commercially available kit
(RNase-Free DNase Set, Qiagen). RNA was stored at -
80°C prior to reverse transcription.
Reverse transcription
The purified RNAs were measured (ND-1000 spectropho-
tometer Nanodrop Technologies) and then 1 μg RNA was
used to prepare cDNA using M-MLV reverse transcriptase
and random primers according to the manufacturer's
instructions (Promega). Samples were stored at -20°C
prior to relative quantification of gene expression.
Primer Design
Transcript sequences were obtained from the National
Centre for Biotechnology Information (Bethesda, MD,
USA) (Tables 1 &2). Equine gene sequences were aligned
to human, bovine and canine sequences using online soft-
ware (http://www.ebi.ac.uk/Tools/clustalw/, http://
www.ensembl.org/) to predict exon boundaries. Primers
were designed using Primer Express (Applied Biosystems)
software and selected to span predicted exon boundaries
where possible. BLAST searches were performed for all
sequences to confirm gene specificity. Target and reference
gene primers were synthesized by Eurogentec. All primers
were validated using a standard curve of five serial dilu-
tions so that all primer efficiencies were between 95–
105% (Tables 1 and 2).
Normalisation of reference genes
The most stable pair of reference gene primers were
selected using the normalization strategy proposed by
[33]. Verification of reference gene selection was carried
out using Normfinder [34]. Reference gene stability pack-
ages were downloaded from geNorm: http://BMC Musculoskeletal Disorders 2009, 10:27 http://www.biomedcentral.com/1471-2474/10/27
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medgen.ugent.be/~jvdesomp/genorm/ and Normfinder:
http://www.mdl.dk/publicationsnormfinder.htm/.
RT-PCR
Real time RT (qPCR) assays were performed in triplicate
using the 7900 HT Fast Real-Time PCR System (Applied
Biosystems; Warrington, UK) in 384 well plates. Reaction
volume in each well was 10 μl (4.6 μl of cDNA, 5 μl of
Power SYBR mastermix (Applied Biosystems), 0.1 μl of
DEPC water 0.15 μl of 3 μM forward primer and 0.15 μl
of 3 μM reverse primer). The cycling conditions com-
prised 10 min polymerase activation at 95°C and 40
cycles at 95°C for 15 sec and 60°C for 60 sec. Data was
then analysed using Sequence Detection Systems Software
v2.2.1 (Applied Biosystems; Warrington, UK).
Statistical analyses
All data were presented as mean ± SE. All data departed
from normality and were therefore log10 transformed. Sig-
nificant differences in gene expression between cartilage,
tendon and bone matched samples were identified using
a mixed effects linear regression model to allow for the
clustering of samples within individual horses (S-Plus
software). Comparisons between gene expression of nor-
mal tissue and developing or diseased or cultured cells
were carried out using a two sample student's t-test where
Table 1: Reference gene primer sequences used for qPCR
Gene SCS Efficiency (%) Sequence
GapDH
AF157626
-3.32 100.2 5'GCATCGTGGAGGGACTCA3'
3'GCCACATCTTCCCAGAGG5'
18S
AJ311673
-3.24 103.3 5'GGCGTCCCCCAACTTCTTA3'
3'GGGCATCACAGACCTGTTATTG5'
ACTB
AF035774
-3.33 99.9 (Bogaerts et al., 2006)
5'CCAGCACGATGAAGATCAAG3'
3'GTGGACAATGAGGCCAGAAT5'
SDHA
DQ402987
-3.29 101.5 5'ACAGAGGAATGGTCTGGAATACTGA3'
3' GTGAGCACCACGTGACTCCTT5'
SCS = Standard Curve Slope
Table 2: Target gene primer sequences use for qPCR
Gene SCS Efficiency (%) Sequence
COL1A2
XM_001492962
-3.31 100.5 5'GCACATGCCGTGACTTGAGA3'
3'CATCCATAGTGCATCCTTGATTAGG5'
COL2A1
NM_001081764
-3.21 105.0 5'TCAAGTCCCTCAACAACCAGATC3'
3'GTCAATCCAGTAGTCTCCGCTCTT5'
COL3A1
XM_001501719
-3.22 104.6 5'ACGCAAGGCCGTGAGACTA3'
3'TGATCAGGACCACCAACATCA5'
COL10A1
XM_001504101
-3.39 97.4 5'TGCCCAGTGGACAGGTTTCT 3'
3'GTCTTTTCGTTTCTAGTCAGATTTTGAA5'
COMP
AF325902
-3.42 95.7 5'GGTGCGGCTGCTATGGAA3'
3'CCAGCTCAGGGCCCTCAT5'
DCN
AB106279
-3.31 100.1 5'CATCCAGGTTGTCTACCTTCATAACA3'
3'CCAGGTGGGCAGAAGTCATT5'
TNC
XR_035757
-3.36 98.6 5'GGGCGGCCTGGAAATG3'
3'CAGGCTCTAACTCCTGGATGATG5'
TMD
AB059407
-3.38 97.4 5'ACGTGACCATGTATTGGATCAATC3'
3'CACCATCCTCCTCAAAGTCTTGT5'
SIX1
XM_001492786
-3.23 104.0 5' GATGCCCCAATGTTTGTGATG3'
3' AGGAGGCATTGCTGACAATCTT5'
SCXB
NM_001105150
-3.35 98.8 5'TCTGCCTCAGCAACCAGAGA3'
3'TCCGAATCGCCGTCTTTC5'
SOX9
XM_001498424
-3.33 99.9 5' CTTTGGTTTGTGTTCGTGTTTTGT3'
3'AGAGAAAGAAAAAGGGAAAGGTAA GTTT5'
OPN
XM_001496152
-3.33 99.9 5'CGCAGATCTGAAGACCAGTATCCT3'
3'TGCTTTCCACAGGTGATGTGA5'
RUNX2
XM_001502519
-3.36 98.4 5'CTGGGCCATGTGTATGATTTGT3'
3'TTTTGACCTGATATAGAGTGCATGGT5'
OMD
XR_035840
-3.26 103.4 5'CAAATTCATCAACCCCTGAAA3'
3'CTTCATCTGGCTCTTGGTCA5'BMC Musculoskeletal Disorders 2009, 10:27 http://www.biomedcentral.com/1471-2474/10/27
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log transformed data were normally distributed. The level
of significance was set at P < 0.05.
Results
Normalisation of reference genes
GeNorm and Normfinder identified Glyceraldehyde -3-
phosphate dehydrogenase (GapDH) and succinate dehy-
drogenase subunit A (SDHA) to be the two most stably
expressed reference genes across normal tendon, cartilage
and bone samples, and both the 2D and 3D in vitro cul-
tures (M = 0.045, V = 0.027). The most stably expressed
reference genes in tendon development and disease were
beta actin (ACTB) and GapDH (M = 0.056, V = 0.057)
(Table 3). When all samples were considered together
GapDH was identified as the most stable gene
(Normfinder ratio 0.050) and ACTB the second most sta-
ble gene (Normfinder ratio 0.072) (Table 3). GeNorm
identified GapDH and ACTB to be the most stable pair of
reference genes (M = 0.127, V = 0.048) (Table 3). As
geNorm and Normfinder were in agreement, gene expres-
sion data was normalised to the average expression of
GapDH and ACTB. The average Ct values used to identify
the most stable reference genes can be seen in Additional
file 1.
Tissue samples
Adult mesenchymal tissues
Figure 1 shows the data obtained for expression levels of
genes presumed to be associated with tendon (a), bone
(b) and cartilage (c). Scleraxis showed significantly higher
expression in tendon than in bone (P = 0.002) (Figure.
1a), and whilst higher levels of expression were identified
in tendon than cartilage this did not reach statistical sig-
nificance. As expected, significantly higher COL1A2 was
expressed in both tendon and bone than in cartilage (P =
0.01 and P = 0.008, respectively) (Figure 1a). Tenomodu-
lin was identified in both tendon and bone but could not
be detected in cartilage. No significant difference could be
identified in the levels tenomodulin expression in tendon
and bone. Tenascin-C expression was significantly lower
in tendon than in bone (P = 0.02). COMP expression was
significantly higher in tendon than in bone (P = 0.02) but
no difference in expression was identified between ten-
don and cartilage (Figure. 1a). Decorin expression was
highest in cartilage (P = 0.03) and lowest in bone (P =
0.02). Osteopontin, Runx2 and osteomodulin were able
to discriminate between tendon and bone (P = 0.003, P =
0.03 and P = 0.01, respectively) (Figure. 1b) but Runx2
was the only hypothesised bone marker that distin-
guished between bone and cartilage (P = 0.007). Of the
cartilaginous markers, only COL2A1 was significantly
lower in tendon than in both bone and cartilage (P =
0.005 and P = 0.0003). Cartilage showed higher expres-
sion of COL10A1 and SOX9 than tendon (P = 0.01 and P
= 0.005 respectively) (Figure. 1c). From the matched nor-
mal tissue samples a panel of COL1A2, scleraxis and
tenascin-C were selected as the most discriminating genes
of tendon phenotype.
Tendon development
Expression of COL1A2 was higher in the foetal tissues
compared to mature tendon relative to reference gene
mRNA (P = 0.01). There was increased tenascin-C expres-
sion in skeletally immature tendon in comparison to
adult tendon (P = 0.02) (Figure. 2a).
Tendon disease
Acute tendinopathy produced significant changes in gene
expression. Tenascin-C expression was greatly increased in
acutely diseased tendon in comparison to normal tendon
(P = 0.0001), although expression of scleraxis and
COL1A1 did not vary. Chronic tendinopathy resulted in a
gene expression profile similar to that of normal tissue
with no significant difference in the expression of
tenascin-C (Figure. 2b).
Table 3: M and V values generated by geNorm and Normfinder
Sample Reference
Genes
M Value
(Gene stability)
V Value
(Pairwise stability)
Normfinder
Tissue GapDH
SDHA
0.045 0.027 0.012
0.018
Developing
Tissue
GapDH
ACTB
0.031 0.020 0.011
0.032
Diseased
Tissue
ACTB
GapDH
0.056 0.057 0.019
0.068
Monolayer
Culture
GapDH
SDHA
0.059 0.085 0.020
0.062
Collagen
Gel
GapDH
SDHA
0.017 0.013 0.006
0.020
All Samples GapDH
ACTB
0.127 0.048 0.050
0.072
Coefficients for tissue samples (tendon, cartilage and bone), developing tendon, diseased tendon, monolayer culture and 3D collagen gels.BMC Musculoskeletal Disorders 2009, 10:27 http://www.biomedcentral.com/1471-2474/10/27
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Gene expression of normal tendon, bone and cartilage samples Figure 1
Gene expression of normal tendon, bone and cartilage samples. (a) Gene expression of COL1A2, scleraxis, tenascin-
C, COMP and decorin in matched samples of tendon, cartilage and bone harvested from normal adult horses. (b) Gene expres-
sion of COL2A1, COL10A1 and SOX9 in matched samples of tendon, cartilage and bone harvested from normal adult horses. 
Relative gene expression data is represented graphically as log transformed values. P values were generated using a mixed 
effects linear regression model to allow for clustering within individual donors. (c) Gene expression of osteopontin, osteonec-
tin and osteomodulin in matched samples of tendon, cartilage and bone harvested from normal adult horses.BMC Musculoskeletal Disorders 2009, 10:27 http://www.biomedcentral.com/1471-2474/10/27
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Gene expression of developing and diseased tendon and in vitro gene expression Figure 2
Gene expression of developing and diseased tendon and in vitro gene expression. (a) Gene expression of COL1A2, 
scleraxis, tenascin-C in SDFT collected from foetuses, yearlings and adults. (b) Gene expression of COL1A2, scleraxis, 
tenascin-C in acute and chronic disease in comparison to normal adult tendon. (c) Gene expression of COL1A2, scleraxis, 
tenascin-C in 2D and 3D in vitro culture in comparison to normal adult tendon. (2D P1 = passage 1 monolayer culture, 2D P5 
= passage 5 monolayer culture, 3D = tendon fibroblasts cultured in collagen gels). P values were generated using a two sample 
student's t-test for normally distributed log transformed data.BMC Musculoskeletal Disorders 2009, 10:27 http://www.biomedcentral.com/1471-2474/10/27
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Cell culture samples
Monolayer cell culture
Scleraxis gene expression was decreased compared to nor-
mal adult tendon at passage 1 of monolayer culture of ten-
don fibroblasts and this significant decrease was
maintained at passage 5 (P = 0.002 and P = 0.004 respec-
tively) (Figure. 2c). No significant differences in COL1A2
and tenascin-C expression were identified between nor-
mal tissue and the 2D in vitro culture systems. Tenomod-
ulin gene expression levels were not detectable in the in
vitro cells.
Three dimensional cell culture in collagen gels
Placing tendon fibroblasts into a three dimensional colla-
gen matrix resulted in increased expression of type I colla-
gen (P = 0.03) compared to passage one monolayer cells.
No significant difference was identified between levels of
COL1A2 and tenascin-C expression by 3D cultured ten-
don fibroblasts and normal adult tendon. However, 3D
cultured tendon fibroblasts showed significantly reduced
expression of scleraxis (P = 0.03) in comparison to normal
adult tendon (Figure 2c).
Discussion
This study has confirmed that a panel of 'marker' genes are
required to identify tendon cell phenotype from other
mesenchymal tissues. The matched adult samples of ten-
don, cartilage and bone show the tensional SDFT to
express high levels of COL1A2 and scleraxis and low levels
of tenascin-C in comparison to the other tissues. Bone
also expresses high levels of COL1A2 but contrastingly
low levels of scleraxis and high levels of tenascin-C. In
contrast, cartilage expresses moderate amounts of
COL1A2, scleraxis and tenascin-C. Tendon regions with a
fibrocartilagenous phenotype that are subjected to com-
pressive loads have been shown to have to have higher
levels of tenascin-C [35-37], for example at the myotend-
inous and osteotendinous junctions [38]. Low levels of
tenascin-C within the mid-body of the normal equine
SDFT identified in the current study are likely to be a
reflection of the tensile loads placed on this region of the
tendon. The presence of scleraxis within equine cartilage
may be a consequence of the inclusion of the perichon-
drium in the samples cartilage, a tissue that is derived
from scleraxis expressing cells [39].
Scleraxis has been described as being an important marker
of tendon neoformation however, there is currently no
evidence that scleraxis can induce tendon neoformation
[40]. Murchison et al (2007) clearly demonstrated the
importance of scleraxis as a transcription factor during
tendon development with scleraxis null mutants exhibit-
ing severe defects in the force transmitting tendons. It has
been suggested that scleraxis is important in directing con-
densations of tendon progenitor cells to form the force
transmitting tendons [26]. The current experiments did
not identify any significant increase in levels of scleraxis
expression in mid-gestational foetal tendons compared to
normal adult tendons. It is possible that once the tendon
phenotype is established during development there is no
further change in scleraxis expression. Alternatively, trans-
lational control of the protein may differ between devel-
oping and adult tendons. Scleraxis expression showed no
significant difference between normal and diseased ten-
dons.
Tendon samples collected from horses with naturally
occurring acute tendinopathy of the SDFT did not show a
significant increase in COL1A2, this may be a result of the
large range in expression levels in the normal adult ten-
don samples, leading to large standard errors. In man,
increased expression of type I collagen has been a consist-
ent finding in acute tendinopathy [41]. Tenascin-C was
significantly increased in the acutely diseased samples;
this is consistent with the appearance of tenascin-C during
the inflammatory phases of wound healing [17,21].
Increased type-I collagen has been reported in chronic
degenerate Achilles tendinopathy [42,43] this is at vari-
ance with the findings of the current study that identified
no significant difference between gene expression of
COL1A2 in normal adult tendon and tendinopathy of the
SDFT of more than 6 mths duration in the horse. This may
reflect differences in clinical condition between painful
degenerate Achilles tendons and healed non-painful
chronic tendinopathy of the equine SDFT. Levels of
tenascin-C mRNA from chronic tendinopathy were not
significantly different from normal adult SDFT demon-
strating that levels of tenascin-C may only increase tran-
siently in acute injury then to return to normal levels.
These findings are at variance with some of the human lit-
erature describing degenerate tendons [8,18] where
increased tenascin-C may be associated with round cells
and a more fibrocartilaginous phenotype or a different
disease state.
Monolayer culture of tendon fibroblasts provides a simple
method to study cell phenotype. Recent investigations
have highlighted significant differences in cellular gene
expression in monolayer compared with three dimen-
sional cultures [44]. The gene expression profile of tendon
fibroblasts in monolayer culture has recently been shown
to alter with progressive passaging [45]. The current exper-
iments have highlighted further differences between mon-
olayer tendon fibroblasts and those found in adult
tendon. Scleraxis expression is decreased at both passage
one and five in monolayer cultures of tendon fibroblasts
hence, neither have a gene expression profile that recapit-
ulates what is found in normal tendon. Three dimen-
sional cell culture methods are thought to more closelyBMC Musculoskeletal Disorders 2009, 10:27 http://www.biomedcentral.com/1471-2474/10/27
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mimic the in vivo cellular environment [30,44]. Unfortu-
nately whilst increasing the expression of COL1A2 in
agreement with the work of others [46] expression of scle-
raxis was not retained when these cells were cultured in
three dimensional collagen gels. The in vitro models used
in the current study did not fully recreate the adult tendon
phenotype. Further work is warranted to identify a culture
system that more closely resembles adult tendon. Recently
embryonic tendon fibroblasts cultured in a three dimen-
sional fibrin gel [47] were able to maintain a tendon
developmental phenotype in the fibrin gel as defined by
electron microscopy. Other three dimensional culturing
systems have been extensively investigated biomechani-
cally [9] however, the gene expression of these alternative
systems has yet to be reported. Clearly, the importance of
recreating the transcriptomic profile of normal tendon rel-
ative to the functional properties of the engineered tissue
requires further evaluation.
The two methods of reference gene stability assessment
were in agreement for all experiments carried out in this
study, this is concordant with previous findings [48].
Interestingly GapDH was identified as one of the most sta-
ble reference genes in vitro while Normfinder found ACTB
to be the most stable reference gene when comparing nor-
mal and diseased tendons.
Conclusion
As no single molecular marker was capable of discriminat-
ing tendon from both bone and cartilage in the current
study it is recommended that multiple genes are used to
identify tenogenic differentiation. The current experi-
ments would suggest high expression of COL1A2 and
scleraxis and low expression of tenascin-C are most repre-
sentative of the normal adult tendon phenotype. Further-
more, this work refutes the use of tenomodulin as a good
marker of equine tendon fibroblasts as similar levels were
identified in both tendon and bone. A genome wide
screen may in the future identify specific markers of ten-
don phenotype. Whether they are maintained in cultured
fibroblasts will also need to be determined.
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